B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

CA14

MOLECULAR TARGET

carbonic anhydrase 14

UniProt: Q9ULX7NCBI Gene: 2363223 compounds

CA14 (carbonic anhydrase 14) is targeted by 23 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting CA14

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Zonisamide2.4010
2Indapamide1.956
3Chlorthalidone1.795
4Histamine1.795
5Sulfanilamide1.614
6benzolamide1.393
7Furosemide1.393
8caffeic acid1.102
9Histidine1.102
10Bumetanide1.102
11Celecoxib1.102
12Vanillic Acid1.102
13Mafenide1.102
14Metolazone1.102
15stx641.102
16Quercetin0.691
17Resveratrol0.691
18Spermidine0.691
19Bortezomib0.691
20Famotidine0.691
21Lacosamide0.691
224-Hydroxybenzoate-3-Monooxygenase0.691
23Spermine0.691

About CA14 as a Drug Target

CA14 (carbonic anhydrase 14) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 23 compounds with documented CA14 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

CA14 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.